Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A
Felicity J Ashcroft, Asimina Bourboula, Nur Mahammad, Efrosini Barbayianni, Astrid J Feuerherm, Thanh Thuy Nguyen, Daiki Hayashi, Maroula G Kokotou, Konstantinos Alevizopoulos, Edward A Dennis and 2 more
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Felicity J AshcroftDepartment of Biology, Norwegian University of Science and Technology, Trondheim, Norway.ORCID 0009-0008-7753-6408
Asimina BourboulaDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, Greece.
Nur MahammadDepartment of Biology, Norwegian University of Science and Technology, Trondheim, Norway.
Efrosini BarbayianniDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, Greece.
Astrid J FeuerhermDepartment of Biology, Norwegian University of Science and Technology, Trondheim, Norway.
Thanh Thuy NguyenDepartment of Biology, Norwegian University of Science and Technology, Trondheim, Norway.
Daiki HayashiDepartment of Applied Chemistry in Bioscience, Graduate School of Agricultural Science, Kobe University, Kobe, Japan.
Maroula G KokotouLaboratory of Chemistry, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece.
Konstantinos AlevizopoulosVentac Partners, Ch. du Vallon 4, Yverdon-les-Bains, Switzerland.
Edward A DennisDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA, USA.ORCID 0000-0003-3738-3140
George KokotosDepartment of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, Greece. gkokotos@chem.uoa.gr.ORCID 0000-0003-3753-7082
Berit JohansenDepartment of Biology, Norwegian University of Science and Technology, Trondheim, Norway. berit.johansen@ntnu.no.ORCID 0000-0003-1901-7614
Funding
Action of Lipolytic EnzymesR35GM139641 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EDWARD A DENNIS · 2021 to 2026
$2.6M
NIGMS NIH HHS R35 GM139641Norges Teknisk-Naturvitenskapelige Universitet (Norwegian University of Science and Technology) NFR235344
6 · The paper itself
Abstract
Eicosanoids are key players in inflammatory diseases and cancer. Targeting their production by inhibiting Group IVA cytosolic phospholipase A
Indexed as
Group IV Phospholipases A2KetonesReactive Oxygen SpeciesAntineoplastic AgentsCell Line, TumorCell SurvivalEnzyme InhibitorsHumansNeoplasmsOxidative StressThiazolesAntineoplastic AgentsEnzyme InhibitorsGroup IV Phospholipases A2KetonesPLA2G4A protein, humanReactive Oxygen SpeciesThiazoles
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.